|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Gilead Sciences (GILD) Q2 Outlook [July 6, 2009]
Gilead (GILD) Thrives Despite Downturn [October 21, 2008]
2009 |
|||
 |
|
|
|
04/21/2009 |
07/21/2009 |
10/20/2009 |
01/26/2010 |
Q1 2009 |
Q2 2009 |
Q3 2009 |
Q4 2009 |
2008 |
|||
|
|
|
|
04/16/2008 |
07/17/2008 |
10/16/2008 |
01/27/2009 |
Q1 2008 |
Q2 2008 |
Q3 2008 |
Q4 2008 |
2007 |
|||
|
|
|
|
01/23/2008 |
10/18/2007 |
7/19/2007 |
4/18/2007 |
Q4 2007 |
Q3 2007 |
Q2 2007 |
Q1 2007 |
Aztreonam Lysine Rejected by FDA [September 20, 2008]
Gilead Should Rise on Penetration, Viread [September 10, 2008]
Gilead Preps for Atripla in Europe [January 24, 2008]
Choosing a Biotech Stock 2: Gilead [September 10, 2007]
Gilead is a biotechnology pharmaceutical company; products include Atripla, Truvada, and Hepsera. So far it has specialized in anti-viral agents for HIV and Hepatitis B.
Gilead Sciences Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.